Tango Therapeutics (TNGX) Operating Income (2020 - 2025)
Historic Operating Income for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $14.1 million.
- Tango Therapeutics' Operating Income rose 14280.07% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 2101.89%. This contributed to the annual value of -$145.6 million for FY2024, which is 2752.14% down from last year.
- Latest data reveals that Tango Therapeutics reported Operating Income of $14.1 million as of Q3 2025, which was up 14280.07% from -$41.0 million recorded in Q2 2025.
- Over the past 5 years, Tango Therapeutics' Operating Income peaked at $14.1 million during Q3 2025, and registered a low of -$42.5 million during Q1 2025.
- Over the past 5 years, Tango Therapeutics' median Operating Income value was -$29.6 million (recorded in 2024), while the average stood at -$26.2 million.
- In the last 5 years, Tango Therapeutics' Operating Income tumbled by 96515423.73% in 2021 and then soared by 14280.07% in 2025.
- Tango Therapeutics' Operating Income (Quarter) stood at -$22.0 million in 2021, then plummeted by 39.04% to -$30.6 million in 2022, then decreased by 14.55% to -$35.0 million in 2023, then fell by 16.84% to -$40.9 million in 2024, then surged by 134.4% to $14.1 million in 2025.
- Its Operating Income stands at $14.1 million for Q3 2025, versus -$41.0 million for Q2 2025 and -$42.5 million for Q1 2025.